Search
Opus Genetics Inc
IRDAdd to Watchlist
4.070USD
+0.010+0.25%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
262.69MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Opus Genetics Inc is 8.59, ranking 27 out of 157 in the Pharmaceuticals industry. The average price target is 8.00, with a high of 9.00 and a low of 6.00.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
10.471
Target Price
+157.26%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Opus Genetics Inc
IRD
17
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Opus Genetics Inc's expected revenue for the next quarter?
Opus Genetics Inc's expected revenue is 2.43M.
What is Opus Genetics Inc's price target?
Analysts forecast that Opus Genetics Inc's price target is USD 8.00, with the highest forecast at USD 9.00 and the lowest forecast at USD 6.00.
How have Opus Genetics IncIRD's recent earnings per share performed?
The market expectation was USD -0.75, while Opus Genetics IncIRD's earnings per share (EPS) for the previous quarter was USD -0.21. EPS for the next quarter is expected at USD -0.16.
What is the analyst rating for Opus Genetics Inc?
Based on the ratings of Opus Genetics Inc's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
